CAREDX, INC. vs QUEST DIAGNOSTICS INC, two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and DGX diverge most: on net margin, CDNA reads -2.0% and DGX reads 9.1%; on return on equity, CDNA reads -2.6% and DGX reads 13.4%. The rest of the comparable metrics sit closer together. What DGX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CDNA | DGX |
|---|---|---|
| Price | $39.73 | $210.80 |
| Market cap | $2.1B | $23.6B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Mature |
| Implied growth (priced in) | — | -2.0% |
| P/E | — | 23.3 |
| P/B | 6.73 | 3.08 |
| P/S | 5.11 | 2.09 |
| EV/EBITDA | — | 10.8 |
| Revenue growth | +19.7% | +11.2% |
| Operating margin | 1.0% | 13.8% |
| Net margin | -2.0% | 9.1% |
| Return on equity | -2.6% | 13.4% |
| Return on assets | -2.0% | 6.1% |
| Return on invested capital | -4.1% | 15.6% |
| FCF yield | 3.3% | 5.6% |
| Dividend yield | — | 0.8% |
| Debt / equity | 0.00 | 0.07 |
| Current ratio | 3.40 | 1.18 |
| Altman Z (solvency) | 5.07 | 7.64 |
| Piotroski F (quality) | 6 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.